Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12

BACKGROUND: While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial) human urothelial carcinoma, also termed non-muscle invasive bladder cancer (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Morillon, Y. Maurice, Su, Zhen, Schlom, Jeffrey, Greiner, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558846/
https://www.ncbi.nlm.nih.gov/pubmed/31186063
http://dx.doi.org/10.1186/s40425-019-0620-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558846/
https://www.ncbi.nlm.nih.gov/pubmed/31186063
http://dx.doi.org/10.1186/s40425-019-0620-2

Ejemplares similares